PHILADELPHIA–(BUSINESS WIRE)–Virion Therapeutics, LLC, a clinical-stage biotechnology company, developing novel T cell-based immunotherapies that utilize checkpoint modifiers, today announced at AASLD’s The Liver Meeting®, in Denver, CO, that an intramuscular prime dose of VRON-0200 alone, its novel, first-in-class, immunotherapy for HBV Functional Cure, induced anti-HBV activity with continued HBsAg declines, without rebound, up to 2+ years post dosing, in all chronically HBV-infected treate
